Skip to main
MRK
MRK logo

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 32 analyst ratings
Buy
Strong Buy 31%
Buy 28%
Hold 38%
Sell 0%
Strong Sell 3%

Bulls say

Merck & Co is projected to return to strong growth by the second half of 2025 and continue this trend into 2026 and 2027, driven by the performance of key products such as Capvaxive and the anticipated launch of clesrovimab for RSV. With a significant focus on the Chinese market, Merck's increased partnership activity in the region is expected to boost its business development and licensing, enhancing market share in key therapeutic areas. The company's optimism surrounding Keytruda’s subcutaneous formulation and ongoing clinical trials for promising therapies like MK-8527 highlight potential revenue protection and growth opportunities amid strong product performances.

Bears say

The negative outlook on Merck & Co's stock is primarily driven by anticipated sales erosion of Keytruda due to competition from biosimilars and the impact of Medicare's IRA price negotiations, with projections indicating a decline of 58% in Keytruda sales post-loss of exclusivity. Additionally, the firm has recently experienced lowered sales expectations for its Gardasil vaccine, compounded by underperformance in new product launches like Winrevair, which fell short of estimates with actual sales of $200 million against projected figures of $256 million and $213 million. Overall, these factors have led to downward revisions in the company's valuation and price targets, reflecting heightened risks to future revenue streams.

Merck (MRK) has been analyzed by 32 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 28% recommend Buy, 38% suggest Holding, 0% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 32 analysts, Merck (MRK) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $110.34, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $110.34, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.